Compare CVV & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | AYTU |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 23.4M |
| IPO Year | N/A | N/A |
| Metric | CVV | AYTU |
|---|---|---|
| Price | $4.11 | $2.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 27.1K | ★ 141.4K |
| Earning Date | 11-10-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $28,251,000.00 | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $2.46 | $0.95 |
| 52 Week High | $4.80 | $3.07 |
| Indicator | CVV | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 75.92 | 66.15 |
| Support Level | $3.03 | $2.65 |
| Resistance Level | $3.99 | $3.07 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 82.38 | 68.53 |
CVD Equipment Corp is engaged in the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used to produce semiconductors and other electronic components. The company operates through the segments of CVD Equipment, CVD materials, and Stainless Design Concepts, MesoScribe. It generates maximum revenue from the CVD Equipment segment. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport, and similar equipment. Company operates in USA, North America, Europe, Middle East and Africa, and Asia-Pacific.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.